Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression

Journal of Virology

Volumn 85, Issue 16, 2011, Pages 8328-8337

  Wang, Ling ^a   Toomey, Ngoc L ^a   Diaz, Luis A ^a   Walker, Gail ^a   Ramos, Juan C ^a   Barber, Glen N ^a   Ning, Shunbin ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON REGULATORY FACTOR 4; INTERFERON REGULATORY FACTOR 7; MESSENGER RNA; MICRORNA; MICRORNA 155; RNA BINDING PROTEIN; SHIP1 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; B CELL INTEGRATION CLUSTER GENE; B LYMPHOCYTE; CELL LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE FUNCTION; GENE INDUCTION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; RNA GENE; RNA INTERFERENCE; T CELL LEUKEMIA; T CELL LYMPHOMA; TRANSACTIVATION; TRANSIENT EXPRESSION; VIRUS CARCINOGENESIS; VIRUS CELL TRANSFORMATION; VIRUS SURVIVAL;

HUMAN HERPESVIRUS 4; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 79961206325     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00570-11     Document Type: Article

References (81)

1. Battistini, A. 2009. Interferon regulatory factors in hematopoietic cell differentiation and immune regulation. J. Interferon Cytokine Res. 29:765-780.
2. Cahir-McFarland, E. D., et al. 2004. Role of NF-κB in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J. Virol. 78:4108-4119.
3. Calin, G. A., and C. M. Croce. 2006. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6:857-866.
4. Cameron, J. E., et al. 2008. Epstein-Barr virus growth/latency III program alters cellular microRNA expression. Virology 382:257-266.
5. Chen, H., et al. 2005. Regulation of expression of the Epstein-Barr virus BamHI-A rightward transcripts. J. Virol. 79:1724-1733.
6. Chen, W., and W. Royer. 2010. Structural insights into interferon regulatory factor activation. Cell. Signal. 22:883-887.
7. Cho, W. C. 2007. OncomiRs: the discovery and progress of microRNAs in cancers. Mol. Cancer 6:60.
8. Du, Z. M., et al. 2011. Upregulation of miR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic marker JMJD1A. PLoS One 6:e19137.
9. Eis, P. S., et al. 2005. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Natl. Acad. Sci. U. S. A. 102:3627-3632.
10. Escalante, C. R., E. Nistal-Villan, L. Shen, A. Garcia-Sastre, and A. K. Aggarwal. 2007. Structure of IRF-3 bound to the PRDIII-I regulatory element of the human interferon-β enhancer. Mol. Cell 26:703-716.
11. Esquela-Kerscher, A., and F. J. Slack. 2006. Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 6:259-269.
12. Faraoni, I., F. R. Antonetti, J. Cardone, and E. Bonmassar. 2009. miR-155 gene: a typical multifunctional microRNA. Biochim. Biophys. Acta Mol. Basis Dis. 1792:497-505.
13. Fitzgerald, K. A., et al. 2003. LPS-TLR4 signaling to IRF3/7 and NF-κB involves the Toll adapters TRAM and TRIF. J. Exp. Med. 198:1043-1055.
14. Fujii, Y., et al. 1999. Crystal structure of an IRF-DNA complex reveals novel DNA recognition and cooperative binding to a tandem repeat of core sequences. EMBO J. 18:5028-5041.
15. Garzon, R., and C. M. Croce. 2008. MicroRNAs in normal and malignant hematopoiesis. Curr. Opin. Hematol. 15:352-358.
16. Gatto, G., et al. 2008. Epstein-Barr virus latent membrane protein 1 transactivates miR-155 transcription through the NF-κB pathway. Nucleic Acids Res. 36:6608-6619.
17. Ghosh, Z., B. Mallick, and J. Chakrabarti. 2009. Cellular versus viral microRNAs in host-virus interaction. Nucleic Acids Res. 37:1035-1048.
18. Gironella, M., et al. 2007. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc. Natl. Acad. Sci. U. S. A. 104:16170-16175.
19. Gottwein, E., et al. 2007. A viral microRNA functions as an orthologue of cellular miR-155. Nature 450:1096-1099.
20. Hammond, S. 2006. RNAi, microRNAs, and human disease. Cancer Chemother. Pharmacol. 58:63-68.
21. Hiscott, J. 2007. Triggering the innate antiviral response through IRF3 activation. J. Biol. Chem. 282:15325-15329.
22. Honda, K., and T. Taniguchi. 2006. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6:644-658.
23. Huye, L. E., S. Ning, M. Kelliher, and J. S. Pagano. 2007. IRF7 is activated by a viral oncoprotein through RIP-dependent ubiquitination. Mol. Cell. Biol. 27:2910-2918.
24. Iida, S., et al. 1997. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat. Genet. 17:226-230.
25. Imig, J., et al. 2011. microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Res. 39:1880-1893.
26. Jiang, J., E. J. Lee, and T. D. Schmittgen. 2006. Increased expression of microRNA-155 in Epstein-Barr virus transformed lymphoblastoid cell lines. Genes Chromosomes Cancer 45:103-106.
27. Kieser, A. 2007. Signal transduction by the Epstein-Barr virus oncogene latent membrane protein 1 (LMP1). Signal Transduct. 7:20-33.
28. Kluiver, J., et al. 2006. Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. Genes Chromosomes Cancer 45:147-153.
29. Kong, W., et al. 2010. MicroRNA-155 regulates cell survival, growth and chemosensitivity by targeting FOXO3a in breast cancer. J. Biol. Chem. 285:17869-17879.
30. Lim, W., K. Gee, S. Mishra, and A. Kumar. 2005. Regulation of B7.1 costimulatory molecule is mediated by the IFN regulatory factor-7 through the activation of JNK in lipopolysaccharide-stimulated human monocytic cells. J. Immunol. 175:5690-5700.
31. Lin, R., Y. Mamane, and J. Hiscott. 2000. Multiple regulatory domains control IRF7 activity in response to virus infection. J. Biol. Chem. 275: 34320-34327.
32. Lu, F., et al. 2008. Epstein-Barr virus-induced miR-155 attenuates NF-κB signaling and stabilizes latent virus persistence. J. Virol. 82:10436-10443.
33. Lu, L. F., et al. 2009. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 30:80-91.
34. Martin, H. J., J. M. Lee, D. Walls, and S. D. Hayward. 2007. Manipulation of the TLR7 signaling pathway by Epstein-Barr virus. J. Virol. 81:9748-9758.
35. Metzler, M., M. Wilda, K. Busch, S. Viehmann, and A. Borkhardt. 2004. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer 39:167-169.
36. Moynagh, P. N. 2005. TLR signalling and activation of IRFs: revisiting old friends from the NFκB pathway. Trends Immunol. 26:469-476.
37. Ning, S., A. D. Campos, B. Darnay, G. Bentz, and J. S. Pagano. 2008. TRAF6 and the three C-terminal lysine sites on IRF7 are required for its ubiquitination-mediated activation by the tumor necrosis factor receptor family member latent membrane protein 1. Mol. Cell. Biol. 28:6536-6546.
38. Ning, S., A. M. Hahn, L. E. Huye, and P. S. Joseph. 2003. Interferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1: a regulatory circuit. J. Virol. 77:9359-9368.
39. Ning, S., L. E. Huye, and J. S. Pagano. 2005. Interferon regulatory factor 5 represses expression of the Epstein-Barr virus oncoprotein LMP1: braking of the IRF7/LMP1 regulatory circuit. J. Virol. 79:11671-11676.
40. Ning, S., L. E. Huye, and J. S. Pagano. 2005. Regulation of the transcriptional activity of the IRF7 promoter by a pathway independent of interferon signaling. J. Biol. Chem. 285:12262-12270.
41. Ning, S., J. Pagano, and G. Barber. IRF7: activation, regulation, modification, and function. Genes Immun., in press.
42. O'Connell, R. M., A. A. Chaudhuri, D. S. Rao, and D. Baltimore. 2009. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc. Natl. Acad. Sci. U. S. A. 106:7113-7118.
43. O'Connell, R. M., D. S. Rao, A. A. Chaudhuri, and D. Baltimore. 2010. Physiological and pathological roles for microRNAs in the immune system. Nat. Rev. Immunol. 10:111-122.
44. O'Connell, R. M., K. D. Taganov, M. P. Boldin, G. Cheng, and D. Baltimore. 2007. MicroRNA-155 is induced during the macrophage inflammatory response. Proc. Natl. Acad. Sci. U. S. A. 104:1604-1609.
45. O'Neill, L. A., F. J. Sheedy, and C. E. McCoy. 2011. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat. Rev. Immunol. 11:163-175.
46. Ovcharenko, D., K. Kelnar, C. Johnson, N. Leng, and D. Brown. 2007. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res. 67: 10782-10788.
47. Panne, D., T. Maniatis, and S. C. Harrison. 2007. An atomic model of the interferon-β enhanceosome. Cell 129:1111-1123.
48. Pedersen, I. M., et al. 2009. Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Mol. Med. 1:288-295.
49. Pedersen, I., and M. David. 2008. MicroRNAs in the immune response. Cytokine 43:391-394.
50. Rai, D., S. W. Kim, M. R. McKeller, P. L. M. Dahia, and R. C. T. Aguiar. 2010. Targeting of SMAD5 links microRNA-155 to the TGF-β pathway and lymphomagenesis. Proc. Natl. Acad. Sci. U. S. A. 107:3111-3116.
51. Ramos, J. C., et al. 2007. IRF4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood 109:3060-3068.
52. Richez, C., et al. 2009. TLR4 ligands induce IFN-α production by mouse conventional dendritic cells and human monocytes after IFN-β priming. J. Immunol. 182:820-828.
53. Rodriguez, A., et al. 2007. Requirement of bic/microRNA-155 for normal immune function. Science 316:608-611.
54. Savitsky, D., T. Tamura, H. Yanai, and T. Taniguchi. 2010. Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol. Immunother. 59:489-510.
55. Selcuklu, S. D., M. T. Donoghue, and C. Spillane. 2009. miR-21 as a key regulator of oncogenic processes. Biochem. Soc. Trans. 37:918-925.
56. Shaffer, A. L., N. C. Emre, P. B. Romesser, and L. M. Staudt. 2009. IRF4: immunity. Malignancy! Therapy? Clin. Cancer Res. 15:2954-2961.
57. Shaffer, A. L., et al. 2008. IRF4 addiction in multiple myeloma. Nature 454:226-231.
58. Sharma, S., et al. 2000. Activation and regulation of interferon regulatory factor 4 in HTLV type 1-infected T lymphocytes. AIDS Res. Hum. Retroviruses 16:1613-1622.
59. Skalsky, R. L., et al. 2007. Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155. J. Virol. 81:12836-12845.
60. Song, Y. J., K. M. Izumi, N. P. Shinners, B. E. Gewurz, and E. Kieff. 2008. IRF7 activation by Epstein-Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3. Proc. Natl. Acad. Sci. U. S. A. 105:18448-18453.
61. Suzuki, S., et al. 2010. Human T cell lymphotropic virus 1 manipulates interferon regulatory signals by controlling the TAK1-IRF3 and IRF4 pathways. J. Biol. Chem. 285:4441-4446.
62. Takaoka, A., T. Tamura, and T. Taniguchi. 2008. Interferon regulatory factor family of transcription factors and regulation of oncogenesis. Cancer Sci. 99:467-478.
63. Tam, W. 2001. Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA. Gene 274:157-167.
64. Tam, W., and J. E. Dahlberg. 2006. miR-155/BIC as an oncogenic microRNA. Genes Chromosomes Cancer 45:211-212.
65. Tamura, T., H. Yanai, D. Savitsky, and T. Taniguchi. 2008. The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 26:535-584.
66. Tang, B., et al. 2010. Identification of MyD88 as a novel target of miR-155, involved in negative regulation of Helicobacter pylori-induced inflammation. FEBS Lett. 584:1481-1486.
67. Thai, T. -H., et al. 2007. Regulation of the germinal center response by MicroRNA-155. Science 316:604-608.
68. Tili, E., C. M. Croce, and J. J. Michaille. 2009. miR-155: on the crosstalk between inflammation and cancer. Int. Rev. Immunol. 28:264-284.
69. Tili, E., et al. 2007. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-α stimulation and their possible roles in regulating the response to endotoxin shock. J. Immunol. 179:5082-5089.
70. van den Berg, A., et al. 2003. High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma. Genes Chromosomes Cancer 37:20-28.
71. Vargova, K., et al. 2011. MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood 117:3816-3825.
72. Xiao, C., and K. Rajewsky. 2009. MicroRNA control in the immune system: basic principles. Cell 136:26-36.
73. Xu, D., L. Zhao, L. Del Valle, J. Miklossy, and L. Zhang. 2008. Interferon regulatory factors 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes. J. Virol. 82:6251-6258.
74. Yamagata, T., et al. 1996. A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. Mol. Cell. Biol. 16:1283-1294.
75. Yamanaka, Y., et al. 2009. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood 114:3265-3275.
76. Yang, L., et al. 2009. Functional analysis of a dominant negative mutation of interferon regulatory factor 5. PLoS One 4:e5500.
77. Yin, Q., et al. 2008. MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways. J. Virol. 82:5295-5306.
78. Yin, Q., X. Wang, J. McBride, C. Fewell, and E. Flemington. 2008. B-cell receptor activation induces BIC/miR-155 expression through a conserved AP-1 element. J. Biol. Chem. 283:2654-2662.
79. Zhang, L., and J. S. Pagano. 2000. Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1. J. Virol. 74:1061-1068.
80. Zhang, L., and J. S. Pagano. 2001. Interferon regulatory factor 7 mediates activation of Tap-2 by Epstein-Barr virus latent membrane protein 1. J. Virol. 75:341-350.
81. Zhao, Y., et al. 2009. A functional microRNA-155 ortholog encoded by the oncogenic Marek's disease virus. J. Virol. 83:489-492.